SCHEMBL4513744

SCHEMBL4513744

O=C(O)NCCCC(=O)Nc1ccc(CC2CCN(C3CCCCC3)C2=O)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.43
POLB P06746 3/20 0.41
HPGD P15428 3/20 0.41
ALDH1A1 P00352 5/20 0.40
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 1/20 0.38
MCHR1 Q99705 2/20 0.37
BRD4 O60885 1/20 0.37
ATAD2 Q6PL18 1/20 0.37
THRB P10828 1/20 0.37
KDM4E B2RXH2 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13674559 0.88 HSD11B1 (0.43) HSD11B1POLBHPGDALDH1A1SMN1; SMN2
SCHEMBL4510127 0.88 HSD11B1 (0.47) HSD11B1POLBHPGDALDH1A1ATM
SCHEMBL13674558 0.88 CA1 (0.43) HSD11B1POLBALDH1A1SMN1; SMN2LMNA
Hydrochloric Acid SCHEMBL4515008 0.88 HSD11B1 (0.42) HSD11B1POLBHPGDALDH1A1SMN1; SMN2
SCHEMBL4513595 0.85 HSD11B1 (0.46) HSD11B1POLBHPGDALDH1A1SMN1; SMN2
SCHEMBL4527041 0.83 LMNA (0.46) HSD11B1POLBHPGDALDH1A1L3MBTL1
SCHEMBL4508949 0.82 HSD11B1 (0.43) HSD11B1POLBHPGDALDH1A1SMN1; SMN2
SCHEMBL4519747 0.82 HSD11B1 (0.46) HSD11B1POLBALDH1A1SMN1; SMN2MCHR1
SCHEMBL4511944 0.81 HSD11B1 (0.52) HSD11B1HPGDALDH1A1SMN1; SMN2KDM4E
SCHEMBL4516607 0.81 HSD11B1 (0.44) HSD11B1POLBHPGDALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885POLB 2628/4885HPGD 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.